These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI. Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298 [TBL] [Abstract][Full Text] [Related]
3. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289 [TBL] [Abstract][Full Text] [Related]
4. Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine. Galldiks N; Dunkl V; Ceccon G; Tscherpel C; Stoffels G; Law I; Henriksen OM; Muhic A; Poulsen HS; Steger J; Bauer EK; Lohmann P; Schmidt M; Shah NJ; Fink GR; Langen KJ Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2377-2386. PubMed ID: 29982845 [TBL] [Abstract][Full Text] [Related]
6. Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-L-tyrosine PET in comparison to MRI. Galldiks N; Rapp M; Stoffels G; Fink GR; Shah NJ; Coenen HH; Sabel M; Langen KJ Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):22-33. PubMed ID: 23053325 [TBL] [Abstract][Full Text] [Related]
7. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas. Moon HH; Kim HS; Park JE; Kim YH; Kim JH BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252 [TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925 [TBL] [Abstract][Full Text] [Related]
9. Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful? Piroth MD; Liebenstund S; Galldiks N; Stoffels G; Shah NJ; Eble MJ; Coenen HH; Langen KJ Mol Imaging; 2013 Sep; 12(6):388-95. PubMed ID: 23981784 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET. Werner JM; Weller J; Ceccon G; Schaub C; Tscherpel C; Lohmann P; Bauer EK; Schäfer N; Stoffels G; Baues C; Celik E; Marnitz S; Kabbasch C; Gielen GH; Fink GR; Langen KJ; Herrlinger U; Galldiks N Clin Cancer Res; 2021 Jul; 27(13):3704-3713. PubMed ID: 33947699 [TBL] [Abstract][Full Text] [Related]
14. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. Piroth MD; Galldiks N; Pinkawa M; Holy R; Stoffels G; Ermert J; Mottaghy FM; Shah NJ; Langen KJ; Eble MJ Radiat Oncol; 2016 Jun; 11():87. PubMed ID: 27342976 [TBL] [Abstract][Full Text] [Related]
15. Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastoma. Nedergaard MK; Michaelsen SR; Perryman L; Erler J; Poulsen HS; Stockhausen MT; Lassen U; Kjaer A Nucl Med Biol; 2016 Mar; 43(3):198-205. PubMed ID: 26924500 [TBL] [Abstract][Full Text] [Related]
16. (18)F-Fluoroethyl-l-Thyrosine Positron Emission Tomography to Delineate Tumor Residuals After Glioblastoma Resection: A Comparison with Standard Postoperative Magnetic Resonance Imaging. Buchmann N; Kläsner B; Gempt J; Bauer JS; Pyka T; Delbridge C; Meyer B; Krause BJ; Ringel F World Neurosurg; 2016 May; 89():420-6. PubMed ID: 26893043 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma. Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307 [TBL] [Abstract][Full Text] [Related]
18. Influence of Bevacizumab on Blood-Brain Barrier Permeability and Stegmayr C; Oliveira D; Niemietz N; Willuweit A; Lohmann P; Galldiks N; Shah NJ; Ermert J; Langen KJ J Nucl Med; 2017 May; 58(5):700-705. PubMed ID: 28153956 [TBL] [Abstract][Full Text] [Related]
19. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[ Harat M; Małkowski B; Roszkowski K Radiat Oncol; 2019 Mar; 14(1):37. PubMed ID: 30832691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]